Animalcare Grp Regulatory News (ANCR)

09 July 2018

Animalcare Group plc

("Animalcare", the "Company" or the "Group")

Cortacare recommended for European marketing approval by CVMP

- Launch in European markets expected in Q4 2018

- Expands Animalcare's dermatology portfolio

Animalcare Group plc (AIM:ANCR), the pan-European animal health business, today announces that it has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), recommending European marketing authorisation for its dermatology product Cortacare. Animalcare plans to launch Cortacare in Q4 2018 through its direct sales operations in seven European countries and international distribution network.

Cortacare is a wholly-owned product, developed by Animalcare as a cutaneous spray for the treatment of inflammatory and pruritic dermatitis in dogs. The product is a corticosteroid designed to be applied topically to reduce inflammation and itching, which complements Animalcare's existing dermatology portfolio. Cortacare accumulates in the dog's skin, allowing for high local activity whilst minimising side effects, and leading to an improvement of skin lesions associated with the condition.

Chris Cardon, CEO of Animalcare Group plc, commented:

"As part of the reprioritisation of our product development pipeline we identified 17 core development products. We are pleased to see the first of these receive a positive recommendation from the CVMP, which paves the way for the commercialisation of this wholly owned product across Europe and expands our existing dermatology portfolio. Product development remains a key area for us and we are focused on building value within our development pipeline. We look forward to announcing further success as the pipeline progresses."

Enquiries:

About Animalcare Group plc

Animalcare is a pan-European sales, marketing and product development company focused on the veterinary and animal health sectors. The Company has operations across Europe with direct sales in seven countries (UK, Belgium, Netherlands, Spain, Portugal, Italy and Germany), and exports to approximately 40 markets worldwide through global partnerships. The Company sells over 300 products including pharmaceuaticals, vaccines and nutraceuticals . Animalcare has a diverse pipeline of products in development and a strong network of distribution and in-license partnerships. For more information, please visit: www.animalcaregroup.co.uk